**Appendix E. Table 3. Evidence Table for primary RLS: Bupropion**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study Characteristics**  **and Design** | **Inclusion/Exclusion criteria** | **Participant Characteristics** | **Intervention (daily dose) /Comparator (daily dose)** | **Risk of bias and Applicability** |
| **Study ID**  **Bayard, 201125**  **Geographical Location**:  USA  **Funding source**: Academic  **Study Design**:  parallel design, fixed-dose  **Duration**: 6 weeks | **Inclusion criteria**:   * Patients also had an International Restless Legs Scale (IRLS) total score ≥15 and meet diagnostic criteria based on 4 screening questions   **Exclusion criteria**:   * history of seizure disorder, alcoholism, suicidal history or ideation * inability to return for 3- and 6-week assessment, no telephone access * eating disorders * age younger than 18 * pregnancy * unwillingness or inability to discontinue current medications for the treatment of RLS. | **N**=60  **Age** (mean yr): 49.3  **Gender** (Male %): 23  **Race/Ethnicity** (%): NR  **Comorbidities**: NR  **Criteria used to define RLS**  IRLSSG  **Baseline Severity**: moderate to severe, baseline mean IRLS score: 26.1  **Previous RLS medication history**: NR but patients but had to complete a 2-week washout period off of the medication before becoming eligible  **Iron Status**: NR | **Intervention:** Bupropion 150 mg  **Comparator:** Placebo  **A.** **Change in Disease Status and Impact**  IRLS Scale Score  **B. Quality of life**  none  **Subjective Sleep Quality**  none  **Definition of clinically significant Improvement:** NR  **Adverse Effects Reported:** partially (withdrawals only) | **Assessment of Internal Validity**  Sequence generation: adequate  Allocation concealment: adequate  Blinding of participants and personnel: yes  Incomplete outcome data: no  **Selective outcome reporting:** no  **Reviewer Comments:** Improvement inIRLS Scale Score from baseline was significant (p=0.16) at week 3 but not week 6. Study was unable to recruit the target of 100 patients (leading possible type II error) |